Cisplatin, a platinum-based chemotherapy agent, is commonly used in treating cancers that may affect women of childbearing age, including cervical cancer, triple-negative breast cancer, and pediatric tumors in adolescents. The authors found that platinum was undetectable in breast milk at 66 hours and beyond following a 70-mg dose of intravenous cisplatin. Relative infant dose of platinum was calculated to be between 0.29% and 0.40% of the maternal dose corrected for body weight. This case demonstrates minimal exposure to platinum via breast milk, following a single 70-mg intravenous dose of cisplatin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041270PMC
http://dx.doi.org/10.1177/0890334413479671DOI Listing

Publication Analysis

Top Keywords

breast milk
12
duration cisplatin
4
cisplatin excretion
4
breast
4
excretion breast
4
milk cisplatin
4
cisplatin platinum-based
4
platinum-based chemotherapy
4
chemotherapy agent
4
agent commonly
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!